Synaptogenix (SNPX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNPX Synaptogenix

Watchlist

3.0150
+0.4500+17.54%

Trading Dec 20 15:11 ET

4.09MMarket Cap3.43P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires13:58 ET
Synaptogenix Shares Jump After Board Forms Special Committee to Explore Strategic Opportunities
MT Newswires11:51 ET
Synaptogenix Restructures Leadership Amid Strategic Refocus
TipRanksDec 20 09:47 ET
Express News | Synaptogenix Inc: Delivery of a Termination Notice Pursuant to Its Agreement to Conduct a Phase 1 Trial of Bryostatin-1 in Multiple Sclerosis
ReutersDec 20 09:26 ET
Express News | Synaptogenix Inc - CEO Alan Tuchman's Salary Reduced to $12,500 per Month
ReutersDec 20 09:24 ET
Express News | Synaptogenix: Submitted a Grant Proposal for Development of Bryostatin-1 With National Institutes of Health
ReutersDec 20 09:19 ET

Comments

Trytosaveabit

Sep 11 08:09

News

$Synaptogenix (SNPX.US)$ Synaptogenix Enters Into Securities Purchase Agreements For A $5M Financing With Existing Investors Involving The Sale Of 5,000 Shares Of Its Newly Issued Series C Convertible Preferred Stock, With A Stated Value Of $1,000 Per Share; The Shares Of Series C Preferred Stock Have An Initial Conversion Price Of $4.00 Per Share And Accrue A 5.0% Quarterly Dividend Payable In Cash

Jaguar8

Jul 18 08:02

NEWS

$Synaptogenix (SNPX.US)$
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...

Trytosaveabit

Jun 26 08:01

News

$Synaptogenix (SNPX.US)$ Reuters· just
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Stock_Drift

Apr 8 22:34

4/9/2024 Watchlist 🚨⚡️🚨⚡️🚨
$Beneficient (BENF.US)$ $Selina Hospitality (SLNA.US)$ $Jaguar Health (JAGX.US)$ $Edible Garden (EDBL.US)$ $Allarity Therapeutics (ALLR.US)$ $Synaptogenix (SNPX.US)$
📊⚡️📊

Heat List

Overall

No Data